Table 5 The base-case analysis results (the lifetime analysis)
| Â | Strategy | cost (PPP$) | QALY | Incremental Cost | Incremental QALY | ICUR (Incremental cost per QALY Gained) PPP$ |
|---|---|---|---|---|---|---|
Cost-Utility analysis | Natalizumab | 354,174.85 | 7.65 | 0 | 0 | – |
rituximab | 58,307.93 | 7.77 | − 295,867 | 0.125 | dominant |